Marketed Products

DRY EYE

REFRESH® Artificial Tears

Artificial tear products for various needs are led by the REFRESH® brand, the No. 1 doctor-recommended brand of artificial tear products⁽¹⁾, which includes: REFRESH PLUS®; REFRESH TEARS®; REFRESH P.M.®; REFRESH DRY EYE THERAPY™; REFRESH CONTACTS®; REFRESH LIQUIGEL®; and REFRESH ENDURA®, the first lubricant eye drop for dry eye that treats all three layers of the tear film. Additionally, Allergan markets REFRESH® CELLUVISC®. Other products marketed throughout the world include the lubricants LIQUIFILM®, CELLUFRESH® and LACRI-LUBE®.

RELIEF®

RELIEF® eye drops quickly remove redness due to dust, smoke and other pollutants and provide protection against further irritation from wind and the sun. This unique formula contains the effective lubricant, polyvinal alcohol, to soothe, cool and protect dry irritated eyes.

RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%

The first and only treatment for increasing tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation. RESTASIS® is the only therapeutic option on the market for people with dry eye disease that goes beyond providing temporary relief for the dryness and treats the underlying cause of the condition — ocular inflammation.

GLAUCOMA

alphagan® (brimonidine tartrate ophthalmic solution) 0.2%

The first alpha-2 agonist approved for the long-term treatment of elevated intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. The ALPHAGAN® franchise is the third largest product line in the glaucoma market worldwide⁽²⁾. The ALPHAGAN® franchise has been a leading therapy for reducing IOP in patients safely and effectively for nearly ten years.

ALPHAGAN® p (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%

Preserved with PURITE®: A formulation containing brimonidine tartrate, a relatively selective alpha-2 agonist, which is the same active ingredient in ALPHAGAN®. ALPHAGAN® P is indicated for the lowering of intraocular pressure (IOP) and is comparable in efficacy to ALPHAGAN® with lower rates of ocular allergy. ALPHAGAN® P 0.1% is a new and improved formulation of the original ALPHAGAN® 0.2% and ALPHAGAN® P 0.15% indicated for lowering IOP in patients with open-angle glaucoma or ocular hypertension.

COMBIGAN™ (brimonidine tartrate/timolol ophthalmic solution)

ALPHAGAN®/timolol combination product indicated for the reduction of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers. COMBIGAN™ is approved outside the United States, in all member states of the European Union, Canada, Australia, Mexico, Brazil and Argentina.

LUMIGAN® (bimatoprost ophthalmic solution) 0.03%

The first synthetic prostamide analog and an important component in the Company’s growing position as a leader in glaucoma management. In the United States, it is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are intolerant of other IOP-lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measures over time) to another IOP-lowering medication.

EXTERNAL DISEASES (ocular infection, inflammation and allergy)

ACULAR® (ketorolac tromethamine ophthalmic solution) 0.5%

A non-steroidal anti-inflammatory (NSAID) used for a range of conditions including ocular allergy, photophobia, post-surgical ocular pain and inflammation.

ACULAR LS® (ketorolac tromethamine ophthalmic solution) 0.4%

The No. 1 prescribed non-steroidal anti-inflammatory (NSAID) in U.S. ophthalmology⁽³⁾, specially formulated to reduce burning and stinging following corneal refractive surgery. ACULAR LS® delivers the proven NSAID performance and provides post-surgical patients with a comfortable recovery.

ALOCRIL® (nedocromil sodium) 2%

A fast-acting mast cell stabilizer approved to treat the itch associated with ocular allergy.

ELESTAT® / RELESTAT® (epinastine HCL ophthalmic solution) 0.05%

A topical antihistamine with mast cell stabilizing activity for the prevention of itching associated with allergic conjunctivitis. The compound inhibits binding to both H1 and H2 histamine receptors, to prevent recruitment and activation of pro-inflammatory medicators that can trigger and exacerbate the ocular allergic response.

OCUFLOX® (fluoroquinolone ofloxacin ophthalmic solution) 0.3%

Indicated for use in bacterial conjunctivitis and corneal ulcers due to susceptible bacteria (marketed as EXOCIN® in Europe and OFLOX® in Latin America).

pred forte® (prednisolone acetate) 1%

A topical anti-inflammatory agent for ophthalmic use.

ZYMAR® (fluoroquinolone gatifloxacin ophthalmic solution) 0.3%

As the first FDA-approved fourth-generation topical fluoroquinolone indicated for the treatment of bacterial conjunctivitis due to susceptible bacteria, ZYMAR® represents a leading advancement in the eye care community in countering emerging antimicrobial resistance. Among U.S. ophthalmologists, ZYMAR® is the No. 1 prescribed fluoroquinolone due to its broad-spectrum activity and optimal formulation⁽³⁾.

(1)	Verispan’s Physician Drug & Diagnosis Audit (PDDA), February 2000 - January 2005.
(2)	Intercontinental Medical Statistics (IMS): (from ~48 countries), Q3 2005, in constant exchange, for the trailing 12 months, as of September 2005.
(3)	Verispan (from the United States only), in U.S. dollars, for the trailing 12 months, as of September 2005.
(4)	Approved in more than 75 countries outside the United States (approved indications vary from country to country).
(5)	McDaniel DH, Neudecker BA, DiNardo JC, Lewis JA II, Maibach HI. Idebenone: a new antioxidant — part I. A relative assessment of oxidative stress protection capacity compared to commonly known antioxidants. J Cosm Derm. 2005; 4(1): 10-17.
(6)	McDaniel DH, Neudecker BA, DiNardo JC, Lewis JA II, Maibach HI. Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone. J Cosm Derm. 2005; 4: 167-173.

Marketed Products

BOTOX® (botulinum toxin type A) for Therapeutic Use

The most widely used botulinum toxin product in the world and the foundation of Allergan’s global leadership in neuromodulator therapy. As the primary treatment for many focal movement disorders since the mid-1980s, indications for BOTOX® have expanded worldwide as scientists and physicians recognize its broad applicability and versatility.

Approved in the United States for:

• Blepharospasm (uncontrollable blinking)
• Cervical Dystonia (painful neck spasm)
• Severe Primary Axillary Hyperhidrosis (excessive sweating) inadequately managed with topical agents
• Strabismus (crossed eyes)

Approved in International Markets⁽⁴⁾ for:

• Adult Post-Stroke Spasticity (increased rigidity in a group of muscles, causing stiffness and restriction of movement)
• Anal Fissure
• Back Pain
• Blepharospasm (uncontrollable blinking)
• Bruxism
• Cervical Dystonia (painful neck spasm)
• Essential Tremor
• Headache
• Hemifacial Spasm (involuntary contraction of facial muscles)
• Hyperhidrosis (excessive sweating)
• Hyperkinetic Facial Lines
• Juvenile Cerebral Palsy (muscles of one or more limbs are permanently contracted and stiff, making normal movement difficult in children)
• Multiple Sclerosis
• Myoclonic Disorders
• Nasal Labial Lines and Upper Facial Lines
• Overactive Bladder
• Spasmodic Dysphonia
• Strabismus (crossed eyes)
• VII Nerve Disorder

(1)	Verispan’s Physician Drug & Diagnosis Audit (PDDA), February 2000 - January 2005.
(2)	Intercontinental Medical Statistics (IMS): (from ~48 countries), Q3 2005, in constant exchange, for the trailing 12 months, as of September 2005.
(3)	Verispan (from the United States only), in U.S. dollars, for the trailing 12 months, as of September 2005.
(4)	Approved in more than 75 countries outside the United States (approved indications vary from country to country).
(5)	McDaniel DH, Neudecker BA, DiNardo JC, Lewis JA II, Maibach HI. Idebenone: a new antioxidant — part I. A relative assessment of oxidative stress protection capacity compared to commonly known antioxidants. J Cosm Derm. 2005; 4(1): 10-17.
(6)	McDaniel DH, Neudecker BA, DiNardo JC, Lewis JA II, Maibach HI. Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone. J Cosm Derm. 2005; 4: 167-173.

Marketed Products

ANTI-WRINKLE TREATMENT

BOTOX® cosmetic and VISTABEL® and VISTABEX™ (botulinum toxin type A)

Indicated for temporary improvement in the appearance of moderate to severe glabellar lines (vertical “frown lines” between the brows) in adult men and women ages 65 and younger.

BREAST AESTHETICS

Breast implant surgery is used for aesthetic augmentation or reconstruction purposes. Domestically, Inamed sells saline-filled breast implants (styles 68, 168, 468 and 363), tissue expanders, and provides silicone gel-filled breast implants through various clinical studies. Internationally, Inamed markets a comprehensive and broad portfolio of breast implant and tissue expander products that include saline-filled and silicone gel-filled breast implants. The innovative Style 410 BIODIMENSIONAL® Cohesive Gel Matrix implants are the company’s flagship product line in these markets. These silicone gel-filled breast implants are primarily sold in Europe, the Middle East, Northern Africa, Latin America, Australia, New Zealand and Asia.

DERMAL FILLER PRODUCTS

CAPTIQUE®

Approved by the FDA in 2004 for the correction of moderate to severe facial wrinkles, CAPTIQUE® is a non-animal stabilized hyaluronic acid dermal filler. Hyaluronic acid is a natural sugar found in all living cells that attracts and binds water, hydrating the skin and giving it volume.

COSMODERM®1 and COSMOPLAST®

The first and only human-based collagen dermal fillers that contain collagen purified from human dermal tissue processed under controlled laboratory conditions. COSMODERM® and COSMOPLAST® are marketed in the United States, Italy, Spain, Canada and New Zealand. These products restore skin structure, smoothing away unwanted lines and wrinkles by replenishing collagen lost with time, exposure to sunlight and other factors. As the first FDA-approved dermal fillers to not require a pre-treatment skin test, they deliver immediate results with no down time.

FACIAL IMPLANTS

Spectrum Facial Implants are designed to provide augmentation or reconstruction of the face, as well as rejuvenation of the aging face. Available in the United States in a full range of styles and sizes for the chin, nose, and cheek, these implants improve results by adding or restoring contours for a balanced and youthful face.

HYLAFORM®, HYLAFORM® plus and HYLAFORM® FINELINE

This dermal filler adds volume to your skin by mimicking the skin’s natural hyaluronic acid. HYLAFORM® provides immediate results and does not require a pre-treatment skin test. HYLAFORM® and HYLAFORM® PLUS were approved in the United States in 2004, while HYLAFORM®, HYLAFORM® PLUS and HYLAFORM® FINELINE are available in numerous markets across Europe, Latin America and Asia Pacific.

JUVÉDERM™

The JUVÉDERM™ dermal filler product line is a full range of products based on non-animal, cross linked, homogenous gel hyaluronic acid-based products. JUVÉDERM™ is available in Canada and several ex-U.S. markets, including the European Union where the product is marketed under the brand name HYDRAFILL™. JUVÉDERM™ has been filed with the FDA for approval in the United States. The product line includes a range of different formulations such as JUVÉDERM™ 18, JUVÉDERM™ 24 and JUVÉDERM™ 30 as well the advanced formulations of JUVÉDERM™ 24HV and JUVÉDERM™ 30HV.

ZYDERM®1, ZYDERM®2 and ZYPLAST®

ZYDERM® and ZYPLAST® injectable collagen implants, introduced in 1981 and 1985, respectively, have set the standard in filler materials for smoothing facial lines, wrinkles and scars and in providing lip border definition.

(1)	Verispan’s Physician Drug & Diagnosis Audit (PDDA), February 2000 - January 2005.
(2)	Intercontinental Medical Statistics (IMS): (from ~48 countries), Q3 2005, in constant exchange, for the trailing 12 months, as of September 2005.
(3)	Verispan (from the United States only), in U.S. dollars, for the trailing 12 months, as of September 2005.
(4)	Approved in more than 75 countries outside the United States (approved indications vary from country to country).
(5)	McDaniel DH, Neudecker BA, DiNardo JC, Lewis JA II, Maibach HI. Idebenone: a new antioxidant — part I. A relative assessment of oxidative stress protection capacity compared to commonly known antioxidants. J Cosm Derm. 2005; 4(1): 10-17.
(6)	McDaniel DH, Neudecker BA, DiNardo JC, Lewis JA II, Maibach HI. Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone. J Cosm Derm. 2005; 4: 167-173.

Marketed Products

AVAGE® (tazarotene cream) 0.1%

A proven treatment to significantly reduce some of the specific signs associated with overexposure to the sun. AVAGE® is approved as an adjunctive agent in the topical treatment of facial fine wrinkling, mottled hypo- and hyper-pigmentation (blotchy skin discoloration), and benign facial lentigines (flat patches of skin discoloration) in patients using a comprehensive skin care and sunlight avoidance program.

AZELEX® (azelaic acid cream) 20%

A mild emollient and moisturizing treatment indicated for mild to moderate acne that allows for use under makeup, moisturizers, sunscreens and other topical medications.

FLUOROPLEX®

Indicated for the treatment of certain skin problems such as actinic (solar) keratoses (small red or skin-color growths that appear as a result of overexposure to the sun).

M.D. FORTE®

A physician-dispensed line of aesthetic skin care products containing alpha hydroxy acids for reducing the appearance of fine facial lines and wrinkles.

PREVAGE® MD

PREVAGE® MD anti-aging treatment contains idebenone 1%, scientifically shown to be the most powerful antioxidant available in a skin care product today⁽⁵⁾. PREVAGE® MD protects the skin from environmental stressors known to cause skin aging including UV light, air pollution, ozone, and cigarette smoke. The antioxidative power of PREVAGE® MD anti-aging treatment has been shown to reduce the appearance of fine lines and wrinkles, as well as skin roughness and dryness, and to even skin tone to restore youthful-looking skin⁽⁶⁾.

TAZORAC® gel / ZORAC® gel (tazarotene gel) 0.05% & 0.1% and TAZORAC® cream (tazarotene cream) 0.05% & 0.1%

A topical receptor-selective retinoid approved for the treatment of psoriasis.

TAZORAC® gel / ZORAC® gel (tazarotene gel) 0.1% and TAZORAC® cream (tazarotene cream) 0.1%

A topical receptor-selective retinoid approved for the treatment of acne.

(1)	Verispan’s Physician Drug & Diagnosis Audit (PDDA), February 2000 - January 2005.
(2)	Intercontinental Medical Statistics (IMS): (from ~48 countries), Q3 2005, in constant exchange, for the trailing 12 months, as of September 2005.
(3)	Verispan (from the United States only), in U.S. dollars, for the trailing 12 months, as of September 2005.
(4)	Approved in more than 75 countries outside the United States (approved indications vary from country to country).
(5)	McDaniel DH, Neudecker BA, DiNardo JC, Lewis JA II, Maibach HI. Idebenone: a new antioxidant — part I. A relative assessment of oxidative stress protection capacity compared to commonly known antioxidants. J Cosm Derm. 2005; 4(1): 10-17.
(6)	McDaniel DH, Neudecker BA, DiNardo JC, Lewis JA II, Maibach HI. Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone. J Cosm Derm. 2005; 4: 167-173.

Marketed Products

OBESITY INTERVENTION PRODUCTS

BIB® System

BioEnterics® Intragastric Balloon (BIB®) System is a non-surgical alternative for the treatment of obesity. Endoscopically placed and inflated with saline, the BIB® System balloon (made of durable, elastic, high-quality silicone) partially fills the stomach to induce the feeling of fullness and support patients in reducing food intake. The BIB® System is available in several European countries; it is not currently available in the United States.

LAP-BAND® System

BioEnterics® LAP-BAND® System (LAP-BAND®) is currently the only minimally invasive surgical approach to treating obesity in the United States. The LAP-BAND® (laparoscopic adjustable gastric band) helps achieve sustained weight loss by placing an adjustable band around the upper part of the stomach to reduce its capacity. Internationally, the LAP-BAND® has been in use since 1993 and is the preferred standard of care in Australia and Europe.

(1)	Verispan’s Physician Drug & Diagnosis Audit (PDDA), February 2000 - January 2005.
(2)	Intercontinental Medical Statistics (IMS): (from ~48 countries), Q3 2005, in constant exchange, for the trailing 12 months, as of September 2005.
(3)	Verispan (from the United States only), in U.S. dollars, for the trailing 12 months, as of September 2005.
(4)	Approved in more than 75 countries outside the United States (approved indications vary from country to country).
(5)	McDaniel DH, Neudecker BA, DiNardo JC, Lewis JA II, Maibach HI. Idebenone: a new antioxidant — part I. A relative assessment of oxidative stress protection capacity compared to commonly known antioxidants. J Cosm Derm. 2005; 4(1): 10-17.
(6)	McDaniel DH, Neudecker BA, DiNardo JC, Lewis JA II, Maibach HI. Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone. J Cosm Derm. 2005; 4: 167-173.